Study to Evaluate Imatinib in Desmoid Tumors
The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.
Aggressive Fibromatosis|Desmoid Tumor
DRUG: Imatinib
Non-progression rate after 6 months of treatment, 6 months
Non-progression rate after 12 and 24 months of treatment, 12 and 24 months|Response rate, 12 and 24 months|Progression-free survival (PFS) and overall survival (OS), 12 and 24 months|Recording of patient quality of life, 12 and 24 months
The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.